DLL3-targeted therapies + TROP2-ADC + HER2-ADC

This is a combination therapy that includes agents targeting three distinct cell surface proteins common in certain cancers, especially small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). **DLL3-targeted therapies** are designed to inhibit or destroy cells expressing Delta-like protein 3 (DLL3), which is upregulated particularly in SCLC. These include antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), chimeric antigen receptor (CAR) T-cell therapies, and radiopharmaceuticals. **TROP2-ADC** refers to ADCs targeting Trophoblast cell-surface antigen 2 (TROP2), a protein overexpressed in various epithelial cancers, with sacituzumab govitecan being a key example. **HER2-ADC** refers to ADCs targeting human epidermal growth factor receptor 2 (HER2), such as trastuzumab deruxtecan (T-DXd), mainly used in HER2-positive solid tumors. The combination exploits multiple mechanisms of action to maximize antitumor activity and minimize resistance, with evidence suggesting improved efficacy over monotherapy. The primary indications are SCLC and NSCLC, with applications in other HER2- and TROP2-expressing tumors being explored[1][2][3][4][5][6][9].